Quick Answer
Senti Biosciences Holdings, Inc. reported Operating Income of -$68.78 million for fiscal year 2025.
Senti Biosciences Holdings, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$68.78M | -12.7% |
| 2024 | -$61.04M | +34.2% |
| 2023 | -$92.73M | -49.4% |
| 2022 | -$62.08M | -53.5% |
| 2021 | -$40.45M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$16.95M | -11.4% | -0.9% |
| June 30, 2025 | -$16.80M | -25.8% | -2.4% |
| March 31, 2025 | -$16.40M | -0.6% | -7.8% |
| September 30, 2024 | -$15.21M | +65.3% | -13.9% |
| June 30, 2024 | -$13.36M | +12.1% | +18.1% |
| March 31, 2024 | -$16.30M | -8.9% | +62.8% |
| September 30, 2023 | -$43.88M | -197.5% | -188.9% |
| June 30, 2023 | -$15.19M | +30.2% | -1.5% |
- Senti Biosciences Holdings, Inc. showed a decrease of -12.7% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Senti Biosciences Holdings, Inc.’s operating income has declined by 70.1% (from -$40.45 million to -$68.78 million).
- The most recent figure is from Senti Biosciences Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: